News & Updates

Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.

Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.

Factors such as older age (>65 years), ventilator use, and higher comorbidity all contribute to increased mortality risk with COVID-19 among patients with epilepsy, as reported in a study.

The combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) with or without ribavirin demonstrates efficacy for the retreatment of patients with hepatitis C virus (HCV) infection in whom prior direct-acting antiviral (DAA) treatment has failed, a study in Egypt has shown.

A 3-month course of prolonged-release pirfenidone formulation appears to be safe and efficacious in the treatment of patients with postacute sequelae of COVID-19 (PASC)-pulmonary fibrosis, as shown in a study.

The rate of tuberculosis (TB) recurrence in children is high, particularly among those living with HIV (CLHIV), suggests a recent study.

Children with rotavirus infection are at risk of developing gastroenteritis with severe but self-limiting neurological manifestations, reveals a study.

Exposure to azithromycin may put patients with COVID‐19 and history of cardiovascular disease (CVD) at higher risks of acute heart failure and death, as reported in a study.

Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).